Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease

Anti-tumor necrosis factor agents (anti-TNF) drugs are commonly used in patients with inflammatory bowel disease (IBD) and have proven effective in both induction and maintenance therapy in luminal Crohn's disease and ulcerative colitis. Their efficacy has also been proven in fistulising perianal Crohn's disease. However, the evidence in other scenarios, such as stricturing, penetrating and non-fistulising perianal Crohn's disease, extraintestinal IBD manifestations and ileoanal reservoir complications, is not as robust. The aim of this review was to perform an analysis of the available literature and to determine the rote of anti-TNF drugs in common clinical practice in patients affected by these complications. (C) 2018 Elsevier Espana, S.L.U. All rights reserved.